Effective January 24, 2022, the FDA updated the Emergency Use Authorization (EUA) fact sheets for two COVID-19 monoclonal antibody treatments: bamlanivimab plus etesevimab (Eli Lilly) and casirivimab plus imdevimab (Regeneron, also known as REGEN-COV). Neither of these treatments are authorized for use anywhere in the U.S. due to their ineffectiveness against the dominant Omicron variant. Sites are directed to immediately stop administering these therapeutics as they do not retain EUA.

Ph: (443) 281-9157

Fax: (410) 582-8728

801 Landmark Dr.
Glen Burnie, MD 21061
Contact Us

Mon-Fri: 8:30AM-6:30PM

Sat: 9:00AM-2:00PM

Facilty COVID-19 Vaccinations

Pre-Registration Form for Facilities

Please fill out our pre-registration form for Facilities. 

DISCLAIMER: Filling out this form does not guarantee your chances of getting the COVID-19 vaccine. Once we have more information, we will contact you personally. Thank you for your interest and stay safe.

covid-vaccination being administered